GlobeNewswire
-
Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies
04/11/2026 -
Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease
04/11/2026 -
Nxera Pharma Revises Consolidated Financial Forecast for the Year Ending 31 December 2026
04/11/2026 -
Breakthrough Therapy Designation granted by the FDA for daridorexant in pediatric insomnia disorder
04/11/2026 -
German hospital introduces miscarriage care device
04/11/2026 -
Novo raises full-year outlook on continued GLP-1 momentum, with third-quarter adjusted operating profit increasing 27% at CER to DKK 31,720 million
04/11/2026 -
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/11/2026 -
Eliminating Static Without Electricity - MEC Industries Introduces the Powerless ECO Ionizer
04/11/2026 -
VitalHub Announces Q3 2026 Conference Call Date
03/11/2026 -
ElderVoice Reports Its AI Phone Companion Alerted a Daughter After Her Mother Said She Was Panicking
04/11/2026 -
Pennant Announces Third Quarter 2026 Earnings Release and Call
04/11/2026 -
Jushi Holdings Inc. Announces Receipt of DEA Registrations for State-Licensed Medical Cannabis Operations
03/11/2026 -
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
03/11/2026 -
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027
03/11/2026 -
Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
03/11/2026 -
Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update
03/11/2026 -
Xenon to Present at Upcoming Investor Conferences
03/11/2026 -
Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272
03/11/2026 -
Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/11/2026
Pages